

MEDICAL POLICY UPDATE



October 2021



IN THIS ISSUE

Criteria Revised for Arthrex Bovine Collagen	2
Criteria Revision for Non-spinal Bone Growth Stimulation	2
Policy Established for Amivantamab-vmjw (Rybrevant)	3



Policy

Criteria Revised for Pain Management of Peripheral Nerves by Injection



Highmark Blue Cross Blue Shield has revised criteria for Z-52, Pain Management of Peripheral Nerves by Injection. Peripheral nerve blocks should be resolved after one (1) to four (4) injections at a specific site. Injections beyond four (4) in a floating 12-month period are considered not medically necessary.

This revised Medical Policy will apply to professional providers and facility claims. The effective date is January 24, 2022.

Place of Service: Inpatient/Outpatient

Please refer to Medical Policy Z-52, Pain Management of Peripheral Nerves by Injection, for additional information.

Updated Criteria for Devices Used for the Treatment of Obstructive Sleep Apnea in Adults



Highmark Blue Cross Blue Shield has established new criteria for E-20 Devices Used for the Treatment of Obstructive Sleep Apnea in Adults. Daytime electrical stimulation devices of the tongue are considered experimental and investigational.

This revised Medical Policy will apply to professional providers. The effective date is January 24, 2022.

Place of Service: Outpatient

Please refer to Medical Policy E-20 Devices Used for the Treatment of Obstructive Sleep Apnea in Adults, for additional information.

Criteria Revised for Arthrex Bovine Collagen



Highmark Blue Cross Blue Shield has revised criteria for S-264, Arthrex Bovine Collagen.

The following criteria is being added to the policy:

Acellular dermal matrix grafts may be considered medically necessary for superior capsular reconstruction when ALL of the following criteria are met:

- Pain unrelieved through non-surgical treatment; **and**
- Decreased mobility; **and**
- Planned procedure includes one of the following:
 - Latissimus dorsi tendon transfer; **or**
 - Lower trapezius tendon transfer.

This revised Medical Policy will apply to professional providers and/or facility claims. The effective date is January 24, 2022.

Place of Service: Inpatient/Outpatient

Please refer to Medical Policy S-264, Arthrex Bovine Collagen, for additional information.

Criteria Revision for Non-spinal Bone Growth Stimulation



Highmark Blue Cross Blue Shield has revised criteria for S-89, Non-spinal Bone Growth Stimulation.

The following criteria is being added to the policy:

- Noninvasive, non-spinal electrical bone growth stimulation may be considered medically necessary as a treatment of failed fusion of the appendicular skeleton when a minimum of nine (9) months has elapsed since the last surgical intervention.

This revised Medical Policy will apply to professional providers and/or facility claims. The effective date is January 24, 2022.

Place of Service: Inpatient/Outpatient

Please refer to Medical Policy S-89, Non-spinal Bone Growth Stimulation, for additional information.

Policy Established for Amivantamab-vmjw (Rybrevant)



Highmark Blue Cross Blue Shield has established new guidelines for I-241, Amivantamab-vmjw (Rybrevant).

This new Medical Policy will apply to professional providers and/or facility claims. The effective date was October 4, 2021.

Place of Service:

Please refer to Medical Policy I-241 Amivantamab-vmjw (Rybrevant) for additional information.

Facility Guidelines added all commercial lines of business for Q-4 Private Duty Nursing



Highmark Blue Cross Blue Shield has updated the facility guidelines across all commercial lines of business for policy Q-4 Private Duty Nursing. The effective date is January 24, 2022.

Place of Service: Outpatient

Please refer to Medical Policy Q-4, Private Duty Nursing, for additional information.



Policy Established for Amivantamab-vmjw (Rybrevant)



NEWS FOR ALL
PROVIDER TYPES

Highmark's Medicare Advantage product has established new criteria for I-250, Amivantamab-vmjw (Rybrevant).



This new Medical Policy will apply to professional providers and facility claims). The effective date was October 4, 2021.

Please refer to Medical Policy I-250, Amivantamab-vmjw (Rybrevant) for additional information.



Comments on These Medical Policies?

We want to know what you think about our new medical policy changes. Send us an email with any questions or comments that you may have on the new medical policies in this edition of Medical Policy Update.

Write to us at medicalpolicy@highmark.com



[eSubscribe](#)



About this Newsletter

Medical Policy Update is a monthly newsletter for the health care providers who participate in our networks and submit claims to Highmark using the appropriate HIPAA transactions or claim forms as required by Highmark. This publication focuses only on medical policy and claims administration updates, including coding guidelines and procedure code revisions, and is the sole source for this information. For all other news, information and updates, be sure to read [Provider News](#), available on the Provider Resource Center at hbcbs.highmarkprc.com.

Highmark Blue Cross Blue Shield is an independent licensee of the Blue Cross and Blue Shield Association. NaviNet is a registered trademark of NaviNet, Inc., which is an independent company that provides a secure, web-based portal between providers and health care insurance companies.

Note: This publication may contain certain administrative requirements, policies, procedures, or other similar requirements of Highmark Inc. (or changes thereto) as well as interpretations of certain administrative requirements, policies and procedures (hereinafter collectively "requirements") which are binding upon Highmark Inc. and its contracted providers. Therefore, the requirements in this publication supplement the Provider Manual. Pursuant to their contract, Highmark Inc. and such providers must comply with any requirements included herein unless and until such item(s) are subsequently modified in whole or in part.